Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

, ESRX

Express Scripts

$70.57

0.51 (0.73%)

08:57
10/11/16
10/11
08:57
10/11/16
08:57

Horizon Pharma sees FY16 adjusted net sales at low end of $1.02B-$1.05B

Consensus $1.03B. Horizon Pharma (HZNP) is providing estimates of certain Q3 results, confirming expected net sales on a non-GAAP adjusted basis at the low end of its previously announced full-year net sales guidance range and revising its full-year 2016 adjusted EBITDA guidance range, reflecting higher fourth-quarter investment spending. The additional operating expenses reflect strategic investments the company is making to support future growth opportunities, particularly as it transitions its business mix toward orphan disease medicines and builds a more durable primary care business, Horizon stated in a regulatory filing. The company anticipates, on a GAAP basis including the previously announced $65M settlement with Express Scripts (ESRX) as a one-time reduction in GAAP net sales, its full-year 2016 net sales will be approximately $960M. Excluding the $65M settlement, the company now expects that net sales on a non-GAAP adjusted basis will be at the low end of its previously announced full-year net sales guidance range of $1.025B-$1.05B, or approximately $1.025B. The exclusion of the $65M settlement from GAAP net sales guidance is the only adjustment reflected in Horizon Pharma's full-year 2016 non-GAAP adjusted net sales guidance. The company is revising its full-year 2016 adjusted EBITDA guidance range as the result of expected net sales at the low end of its non-GAAP adjusted net sales guidance range and anticipated higher investment spending in the fourth quarter of 2016 and now expects adjusted EBITDA to be in the range of $450M-$460M, prior range was $495M-$510M. The company's full-year 2016 guidance does not include the previously announced expected acquisition of Raptor Pharmaceutical Corp.

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

ESRX

Express Scripts

$70.57

0.51 (0.73%)

  • 26

    Oct

  • 06

    Nov

  • 14

    Dec

HZNP Horizon Pharma
$19.52

0.79 (4.22%)

08/02/16
BMOC
08/02/16
NO CHANGE
BMOC
Outperform
Horizon Pharma scored 'important win' with CVS, says BMO Capital
BMO Capital analyst Gary Nachman said Horizon Pharma (HZNP) securing covered status for Duexis and Vimovo with CVS/Caremark (CVS) is an "important win" for the drugmaker that demonstrates it is improving its execution on the managed care front. While Express Scripts (ESRX) still has Duexis and Vimovo on its exclusion list for 2017, Horizon indicated that it is still in discussions that have been "constructive," noted Nachman, who keeps an Outperform rating on Horizon shares.
09/13/16
BMUR
09/13/16
NO CHANGE
Target $32
BMUR
Buy
Horizon Pharma acquisition a positive, says Brean Capital
Brean Capital analyst Difei Yang said she is positive on Horizon Pharma's (HZNP) deal for Raptor Pharmaceuticals (RPTP). The analyst cited Horizon executing on its transformative strategy into an orphan disease company, the reasonable price paid for the company, and the moderate growth opportunities for synergies between the two. Yang reiterated her Buy rating and raised her price target to $32 from $30 on Horizon Pharma shares.
09/30/16
JMPS
09/30/16
NO CHANGE
JMPS
Horizon Pharma patent loss immaterial, says JMP Securities
After the U.S. Patent and Trademark Office ruled that Horizon Pharma's '215 patent for Ravicti is unpatentable, JMP Securities analyst Donald Ellis says the news is not material. He says that Ravicti still has orphan drug exclusivity until 2020, and that the company has five other patents on the drug that will last until 2032. He recommends buying Horizon on any weakness.
10/03/16
BMOC
10/03/16
NO CHANGE
BMOC
Horizon Pharma added to US Small Cap Fundamental List at BMO Capital
ESRX Express Scripts
$70.57

0.51 (0.73%)

08/09/16
LEER
08/09/16
NO CHANGE
Target $110
LEER
Outperform
Leerink remains positive on CVS Health long-term fundamentals
Leerink analyst David Larsen continues to be positive on CVS' (CVS) long-term fundamentals. The analyst notes that the company is having a successful 2017 selling season, with a retention rate higher than what it was last year, and says its Q3 should benefit from a number of break-even generics. Further, Larsen says the company is being more aggressive than Express Scripts (ESRX) with regards to formulary management, and believes that if CVS provides a 5-year outlook in December, shares will likely rally. Larsen reiterates an Outperform rating and $110 rating on CVS' shares.
08/15/16
LEER
08/15/16
NO CHANGE
LEER
Outperform
Leerink more positive on CVS after Formulary exclusions lists
Leerink analyst David Larsen says he's incrementally more positive on CVS Health (CVS) after the company and Express Scripts (ESRX) published their 2017 National Preferred Formulary exclusions lists. CVS is being more aggressive about using bio-similar products and has excluded about 10 products due to hyperinflation trends, Larsen tells investors in a research note. Express Scripts is excluding around 85 products in 2017, which is almost half of the 153 products being excluded by CVS, the analyst writes. He keeps an Outperform rating on CVS and a Market Perform ration on Express Scripts.
08/29/16
LEER
08/29/16
NO CHANGE
LEER
EpiPen price is Mylan's issue, says Leerink
Leerink analyst David Larsen says the recent weakness in pharmacy benefit managers and the drug distribution group is "overdone," as he believes Mylan (MYL) has been taking the vast majority of the pricing increases that have occurred with EpiPen, not the pharmacy benefit managers and distributors. Further, the analyst estimates that Cardinal Health (CAH) has a "fee-for-service" deal with EpiPen, which means that there may be no benefit to the company for any price increase that occurs, and notes that Express Scripts (ESRX) gives back 80%-90% of EpiPen rebates to their plan customers. Larsen would be a buyer of CVS Health (CVS) on weakness.
10/05/16
UBSW
10/05/16
INITIATION
Target $76
UBSW
Neutral
Express Scripts initiated with a Neutral at UBS
Target $76.

TODAY'S FREE FLY STORIES

07:50
09/22/17
09/22
07:50
09/22/17
07:50
General news
Fedspeak returned from the blackout period »

Fedspeak returned from…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:49
09/22/17
09/22
07:49
09/22/17
07:49
Hot Stocks
Phillips 66 Partners to sell $750M of Series A preferred units »

Phillips 66 Partners LP…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Phillips 66 Partners announces $2.4B acquisition of interests from Phillips 66 »

Phillips 66 Partners…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Recommendations
Versartis analyst commentary  »

Cantor still sees 55%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Downgrade
Exelixis rating change  »

Exelixis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners »

Phillips 66 Partners to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$24.66

-1.13 (-4.38%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Technical Analysis
Technical View: U.S. Steel falls in early trading, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:45
09/22/17
09/22
07:45
09/22/17
07:45
Recommendations
Zimmer Biomet analyst commentary  »

Value investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/22/17
09/22
07:45
09/22/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

, TCEHY

Tencent

$44.15

-0.15 (-0.34%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Periodicals
Alibaba, Tencent look towards emerging markets in mobile-payments race, WSJ says »

Chinese companies Alibaba…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

TCEHY

Tencent

$44.15

-0.15 (-0.34%)

AAPL

Apple

$153.39

-2.68 (-1.72%)

GOOG

Alphabet

$932.45

0.87 (0.09%)

GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

SPR

Spirit AeroSystems

$78.90

0.76 (0.97%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Spirit AeroSystems to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AERI

Aerie Pharmaceuticals

$51.45

-1.95 (-3.65%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie pullback on AdComm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

CSCO

Cisco

$32.70

0.1 (0.31%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Cisco management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

EFX

Equifax

$98.25

2.25 (2.34%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Technical Analysis
Technical View: Equifax trades higher, analyst action »

Shares are back well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AA

Alcoa

$46.25

-1.25 (-2.63%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Downgrade
Alcoa rating change  »

Alcoa downgraded to Hold,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.84

0.17 (0.25%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Earnings
CarMax reports Q2 EPS 98c, consensus 95c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

SYK

Stryker

$140.67

-2.04 (-1.43%)

, ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Recommendations
Stryker, Zimmer Biomet analyst commentary  »

Growth investors should…

SYK

Stryker

$140.67

-2.04 (-1.43%)

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SAVE

Spirit Airlines

$34.01

1.31 (4.01%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Conference/Events
Spirit Airlines to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

IBM

IBM

$145.26

-0.62 (-0.43%)

, WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Hot Stocks
IBM announces new agreement with Walgreens to deploy IBM retail analytics »

IBM (IBM) announced a new…

IBM

IBM

$145.26

-0.62 (-0.43%)

WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 23

    Sep

  • 22

    Oct

  • 25

    Oct

  • 15

    Nov

07:38
09/22/17
09/22
07:38
09/22/17
07:38
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

07:37
09/22/17
09/22
07:37
09/22/17
07:37
Conference/Events
Federal Reserve Bank of Kansas City President to speak at conference »

Kansas City Federal…

MYGN

Myriad Genetics

$33.61

0.1 (0.30%)

07:36
09/22/17
09/22
07:36
09/22/17
07:36
Recommendations
Myriad Genetics analyst commentary  »

Myriad Genetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.